Innate Pharma Q3 2026 Business Update and Financial Results - INNATE PHARMA SA

Financial Performance:

• Secured a €75 million (approx. $80M based on context, though transcript says "75 million") upfront payment from the strategic partnership with SOBI for lacutamab.
• Total cash position as of September 30, 2026, stands at $96.8 million.
• Runway extended through the end of Q1 2028 based on current cash on hand.
• Received $450 million to date under the AstraZeneca partnership for monalizumab.
• Potential future milestones with AstraZeneca total up to $825 million, with double-digit royalties outside Europe and 50% profit sharing in Europe.
• Eligible for up to $40 million in near-term milestones for lacutamab's esophageal cancer indication and up to $465 million for SOBI's option to acquire full global rights.

Guidance and Future Outlook:

• Telemac-3 Phase 3 study for lacutamab initiated; first patient dosing expected in Q1 2027.
• Filing for accelerated approval for lacutamab in esophageal cancer targeted for H2 2027, with potential approval in H1 2028.
• Monalizumab Phase 3 Pacific-9 study expected to read out in H1 2027; enrollment is complete.
• IPH4502 Phase 1 data scheduled for presentation at the EORTC-NCI-AACR Symposium on November 18, 2026.
• Long-term strategy focuses on a differentiated Next-Generation ADC portfolio utilizing proprietary stable linkers, bispecific designs, and dual-payload approaches.

Business Segments and Product Lines:

• Lacutamab (Anti-LAG3): Strategic partnership with SOBI is effective; Innate retains development rights, SOBI holds global commercialization rights upon potential accelerated approval in esophageal cancer. Phase 3 covers both esophageal cancer and cutaneous T-cell lymphoma (CTCL).
• IPH4502 (Nectin-4 ADC): Phase 1 dose escalation complete; shows preliminary antitumor activity and favorable safety in heavily pre-treated patients. Designed to address limitations of first-generation Nectin-4 ADCs via a unique linker and non-overlapping epitope binding.
• Monalizumab (NKG2A): Co-developed with AstraZeneca in Non-Small Cell Lung Cancer (NSCLC); supported by three prior Phase II studies (COAST, NEO-COAST, NEO-COAST2).
• ADC Pipeline: Developing a broader pipeline of differentiated candidates including dual-targeted bispecific ADCs, bispecific ADCs with enhanced internalization, and dual-payload ADCs.

Market and Competitive Landscape:

• Market positioning for IPH4502 emphasizes differentiation against current Nectin-4 ADCs (e.g., Enhertu) through a stable linker and unique antibody epitope.
• Competitive landscape in head and neck oncology noted with analyst inquiries regarding EGFR bispecifics; Innate maintains that current data across tumor types requires holistic review before drawing specific conclusions.
• Pacific-9 study results are critical for validating monalizumab's efficacy in unresectable stage III NSCLC compared to standard of care (durvalumab).

Risks and Challenges:

• Clinical Delays: The Pacific-9 study readout has been delayed due to slower event accumulation; management cautions against speculating on performance outcomes (experimental vs. control arm) from this delay.
• Event-Driven Uncertainty: Progress on monalizumab depends on the completion of blinded efficacy events, making precise timing difficult to predict.
• Key Personnel Departure: CFO Frederic Lombard announced his departure at the end of December 2026; a succession search has been initiated.
• Development Risk: Reliance on successful Phase 3 outcomes for regulatory approvals and milestone payments.

Management Commentary and Tone:

• Tone: Confident and focused on executing near-term catalysts while maintaining a strong financial position.
• Strategy: Emphasis on portfolio consolidation and leveraging strategic partnerships (SOBI, AstraZeneca) to de-risk development and fund future growth.
• Transparency: Management explicitly stated that the delay in Pacific-9 data should not be interpreted as a signal of over- or under-performance by either study arm.

Analyst Questions and Answers:

• IPH4502 Data Expectations (Dana Graybosh, LeeRank Partners): Asked about expected outcomes for the EORTC-NCI-AACR presentation. Management clarified the study involved 76 patients across >10 tumor types, focusing on safety profiling and efficacy signals in urothelial, NSCLC, and head and neck cancers, but deferred specific data details to the poster session.
• Pacific-9 Delay and Next Steps (Jeet Mukherjee, U.S. Bank/BTIG): Asked about implications of the Pacific-9 delay and IPH4502 next steps. Management reiterated that the delay is typical for event-driven trials and offers no insight into treatment arm performance; next steps for IPH4502 will be detailed at the November 18th KOL event.
• Head and Neck Opportunity: Analyst inquired about the head and neck market given recent EGFR bispecific successes; management responded that data is currently limited per tumor type and requires a holistic review of the basket study.

Other Key Points:

• Corporate Governance: Announcement of the departure of CFO Frederic Lombard after nearly six years of service; a search for a successor is underway.
• Event Hosting: Innate will host a hybrid event in London on November 18, 2026, alongside the EORTC-NCI-AACR symposium to discuss IPH4502 data.
• Pipeline Strategy: The company is actively building a next-generation ADC portfolio to address tumor antigen heterogeneity and resistance mechanisms.